Deciphera Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Biopharmaceuticals (Oncology)
Strategic Profile
The lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company has the potential to reach $1 billion in peak revenue with QINLOCK and vimseltinib, establishing itself as a multi-product commercial-stage enterprise.
Cyborg Score Rationale
As a subsidiary of Ono Pharmaceutical Co Ltd, Deciphera operates as a commercial-stage biopharmaceutical company. The company has demonstrated strong commercial execution with validated kinase inhibitor portfolio and access to significant parent company resources, though it now operates under a larger pharma umbrella post-acquisition (April 2024).
Top Insights
Acquired by ONO Pharmaceutical in April 2024 for $2.4 billion equity value, transitioning to subsidiary status
QINLOCK achieved $46.0 million in Q4 2023 net product revenue, up 40% year-over-year
Pipeline includes three clinical-stage and two research-stage kinase-inhibiting drug programs targeting cancer and immunological diseases
Post-acquisition, Deciphera will operate as a standalone business of ONO Group from Waltham headquarters
Named Competitors
Gleevec — Kinase inhibitor for gastrointestinal stromal tumors and chronic myeloid leukemia
Sutent — Multi-kinase inhibitor for renal cell carcinoma and gastrointestinal stromal tumors
Tasigef — Kinase inhibitor for various solid tumors and hematologic malignancies
Recent Developments
(April 2024) Acquired by ONO Pharmaceutical for $2.4 billion
(January 2024) Cash runway extended into second half of 2026 with $352 million in liquid assets
(August 2023) Dashyant Dhanak appointed Executive Vice President and Chief Scientific Officer
Open the full interactive Deciphera Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.